Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra, Inc. reported strong growth for the fourth quarter and full year 2025, highlighted by rising revenue and improved profitability. Fourth quarter revenue reached $385.4 million, up 22.1% from a year earlier, with net income of $47.3 million and an adjusted EBITDA margin of 20.5%.
For 2025, revenue grew to $1,403.7 million, an increase of 17.5%, while net income climbed to $177.7 million, or $4.52 per diluted share, and adjusted EBITDA was $266.8 million with a 19.0% margin. Thrombectomy and embolization products both delivered double-digit growth. Because of the proposed acquisition of Penumbra by Boston Scientific Corporation, the company is not providing 2026 guidance and will not host a conference call.
Grewal Harpreet reported acquisition or exercise transactions in this Form 4 filing.
Penumbra director Harpreet Grewal received a grant of 589 shares of common stock in the form of restricted stock units at no cost. The RSUs vest in four equal parts on March 31, June 30, September 30 and December 31 2026, if he continues serving as a director.
If the closing of the previously signed merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs will fully vest at that closing, again subject to his continued service. After this award, he directly holds 8,819 Penumbra shares, with a portion still subject to vesting.
Penumbra Inc director Arani Bose reported an equity award and updated share holdings. On February 13, 2026, Dr. Bose acquired 589 shares of common stock through a grant or award with a price of $0.00 per share, bringing his directly held total to 1,147 shares.
Footnotes explain these are restricted stock units vesting in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to his continued board service. Any unvested units will fully vest if the merger closing described in the cited Agreement and Plan of Merger occurs while he remains a director. The filing also notes 258,462 shares of common stock are held indirectly through Bose Family Holdings II, LLC.
Leeds Janet reported acquisition or exercise transactions in this Form 4 filing.
Penumbra Inc director Janet Leeds received an equity grant of 589 shares of common stock in the form of restricted stock units (RSUs) at no cash cost. The award increases her directly held shares to 6,639.
The RSUs vest in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, as long as she continues serving as a director through each date. If the Closing of the referenced merger with Boston Scientific Corporation occurs, any RSUs still unvested at that time will fully vest at Closing, again conditioned on her continued board service.
O'Rourke Bridget reported acquisition or exercise transactions in this Form 4 filing.
Penumbra director Bridget O'Rourke reported an equity award of 589 shares of common stock in the form of restricted stock units (RSUs). The award was granted at no cash cost and increased her directly held common stock to 5,962 shares after the transaction.
The RSUs vest in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, as long as she continues serving as a director through each date. If the Closing of the merger with Boston Scientific Corporation described in the merger agreement occurs, any unvested RSUs will fully vest at that Closing, subject to her continued board service through that date.
Sarna Surbhi reported acquisition or exercise transactions in this Form 4 filing.
Penumbra Inc director Surbhi Sarna reported an equity award of 589 shares of common stock in the form of restricted stock units (RSUs). The grant was recorded at a price of $0.00 per share, reflecting a stock-based compensation award rather than an open-market purchase.
The RSUs are scheduled to vest in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to her continued service as a director through each date. The filing states that if the Closing of the merger described in the January 14, 2026 Agreement and Plan of Merger among Penumbra, Boston Scientific Corporation, and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs will fully vest at that Closing, again conditioned on her continued board service through that date. After this grant, she reports beneficial ownership of 4,293 shares of Penumbra common stock, a portion of which remains subject to vesting.
Penumbra director Thomas Wilder reported an equity award and updated holdings. He acquired 589 shares of common stock via restricted stock units granted at no cost, which vest in four equal installments on March 31, June 30, September 30, and December 31, 2026. The filing also notes 4,506 shares held indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
Penumbra Inc executive Johanna Roberts, EVP, General Counsel & Secretary, reported equity compensation activity in the form of restricted stock units (RSUs) and related tax withholding. On February 13, 2026, she was granted 2,630 RSUs that vest in four equal installments on February 15 of 2026, 2027, 2028 and 2029, subject to continued service. On February 17, 2026, she received another 2,630 RSUs, vesting annually in four equal installments beginning February 15, 2027, also subject to continued service. The footnotes state that if the Closing of the merger agreement among Penumbra, Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs from these grants will fully vest at that Closing, provided she remains in service through that date. In connection with RSU vesting, 482 shares of common stock were disposed of at $339.30 per share to cover tax withholding obligations, a non-open-market, tax-withholding disposition. Following these transactions, she directly owned tens of thousands of Penumbra common shares, with portions subject to vesting.
Penumbra Inc Chief Financial Officer Maggie Yuen reported multiple equity-related transactions in company common stock. On February 13, 2026, she was granted 2,630 restricted stock units (RSUs) under Penumbra’s Amended and Restated 2014 Equity Incentive Plan, scheduled to vest in four equal annual installments starting February 15, 2026, subject to continued service. On February 17, 2026, she received an additional 2,630 RSUs, vesting annually beginning February 15, 2027, also subject to continued service. Any unvested RSUs from these grants will fully vest if the Closing of the merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., as defined in the January 14, 2026 merger agreement, occurs while she remains in service. In connection with RSU vesting, 481 shares of common stock were withheld by Penumbra on February 15, 2026 at $339.30 per share to satisfy tax withholding obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, Yuen directly owned 20,785 shares of Penumbra common stock.
Penumbra Inc Chief Accounting Officer Lambert Shiu reported multiple equity compensation transactions involving company common stock. On February 13, 2026, he was granted 2,300 restricted stock units (RSUs) at $0 under Penumbra's Amended and Restated 2014 Equity Incentive Plan, with one quarter scheduled to vest on each of February 15, 2026, 2027, 2028 and 2029, subject to continued service. On February 17, 2026, he received an additional 2,300 RSUs at $0, vesting in four equal annual installments beginning February 15, 2027, also subject to continued service.
The filing notes that if the Closing defined in the January 14, 2026 merger agreement with Boston Scientific Corporation occurs, any unvested RSUs from these grants will fully vest at that Closing, provided he remains in service through that date. On February 15, 2026, 412 shares of common stock were disposed of at $339.30 per share to satisfy tax withholding obligations related to RSU vesting, rather than an open-market sale. After these transactions, he directly owned 39,473 shares of Penumbra common stock, a portion of which remains subject to vesting, and an additional 300 shares are held indirectly through his spouse's IRA.